2SEVENTY BIO INC's ticker is and the CUSIP is 901384107. A total of 4 filers reported holding 2SEVENTY BIO INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $174 | +278.3% | 44,436 | +879.2% | 0.01% | +250.0% |
| Q2 2023 | $46 | -2.1% | 4,538 | -0.5% | 0.00% | 0.0% |
| Q1 2023 | $47 | +9.3% | 4,562 | -0.4% | 0.00% | 0.0% |
| Q4 2022 | $43 | -99.9% | 4,579 | -10.9% | 0.00% | -33.3% |
| Q3 2022 | $75,000 | -2.6% | 5,140 | -11.5% | 0.00% | +50.0% |
| Q2 2022 | $77,000 | -21.4% | 5,807 | +1.5% | 0.00% | 0.0% |
| Q1 2022 | $98,000 | -41.7% | 5,724 | -12.8% | 0.00% | -33.3% |
| Q4 2021 | $168,000 | – | 6,566 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,738,972 | $38,137,514 | 4.92% |
| Newtyn Management, LLC | 1,505,000 | $15,351,000 | 3.02% |
| CHI Advisors LLC | 855,000 | $8,721,000 | 2.32% |
| AlphaCentric Advisors LLC | 302,500 | $3,085,500 | 2.13% |
| Bain Capital Life Sciences Investors, LLC | 1,408,901 | $14,371 | 1.80% |
| Casdin Capital, LLC | 2,023,913 | $20,643,913 | 1.70% |
| Saturn V Capital Management LP | 172,188 | $1,756,318 | 1.31% |
| Iron Triangle Partners LP | 868,939 | $8,863,178 | 1.28% |
| SECTORAL ASSET MANAGEMENT INC | 476,000 | $4,855,200 | 0.93% |
| Lion Point Capital, LP | 170,000 | $1,734,000 | 0.71% |